Lantern Pharma (LTRN) Non-Current Deferred Tax Liability (2020 - 2021)
Lantern Pharma's (LTRN) quarterly Non-Current Deferred Tax Liability came in at $5054.0 in Q4 2021, down 18.97% on a YoY basis from $6237.0 in Q4 2020, and down 18.97% quarter-over-quarter from $6237.0 in Q4 2020.
Powered by 
Analysis
Lantern Pharma (LTRN) Non-Current Deferred Tax Liability (2020 - 2021) Analysis & Trends
Lantern Pharma (LTRN) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $5054.0 the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Non-Current Deferred Tax Liability fell 18.97% year-over-year to $5054.0; the trailing twelve-month figure through Dec 2021 stood at $5054.0 (down 18.97% YoY), and the FY2021 full-year result was $5054.0, down 18.97% from the prior year.
- Non-Current Deferred Tax Liability fell to $5054.0 in Q4 2021 per LTRN's latest filing, from $6237.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $6237.0 in Q4 2020 and bottomed at $5054.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Lantern Pharma | 21.99 Mn | 21.99 Mn | - |